Cardio Diagnostics’ Whitepaper Examines Clinical Blind Spot in Coronary Heart Disease Detection and Care
Business Wire•12/11/2026•08:25 ET
0
Key Highlights
- ➤Cardio Diagnostics (CDIO) released a whitepaper on non-obstructive coronary artery disease.
- ➤INOCA affects approximately 3-4 million Americans, according to the WISE study.
- ➤Epigenetics-based testing may help identify INOCA earlier in primary care.
- ➤PrecisionCHD is being supported by growing evidence for coronary heart disease detection.
Expert Statements
Robert Philibert, Co-Founder and Chief Medical Officer of Cardio Diagnostics
“Coronary heart disease can result from obstructed flow in large or small blood vessels, yet invasive angiography can only detect blockages in the larger cardiac arteries.”
Robert Philibert, Co-Founder and Chief Medical Officer of Cardio Diagnostics
“This whitepaper outlines a clear clinical pathway for a suspected INOCA patient and how methods such as epigenetics-based testing may help identify them earlier.”
Cardio Diagnostics’ Whitepaper Examines Clinical Blind Spot in Coronary Heart Disease Detection and Care
An angiogram can miss the full clinical picture of coronary heart disease for patients without significant blockage in the large coronary arteries. But epigenetics-based testing may help identify these patients earlier.
Get started
Create a free account to read the full story.